Who are olmesartan medoxomil and a CCB's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): valsartan/amlodpine, olmesartan medoxomil / amlodipine or azelnidipine, valsartan/amlodipine, Candemore Plus Tab, Candesartan cilexetil/Amlodipine besylate, Olmesartan/amlodipine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/olmesartan-medoxomil-and-a-ccb.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

olmesartan medoxomil and a CCB — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

olmesartan medoxomil and a CCB (olmesartan medoxomil and a CCB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor blocker / Calcium channel blocker combination. Area: Cardiovascular.

marketed Angiotensin II receptor blocker / Calcium channel blocker combination AT1 receptor; L-type voltage-gated calcium channel Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

olmesartan medoxomil and a CCB (olmesartan medoxomil and a CCB) — Daiichi Sankyo Co., Ltd.. This combination blocks angiotensin II receptors and calcium channels to reduce blood pressure through dual vasodilation and reduced vascular resistance.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
olmesartan medoxomil and a CCB TARGET	olmesartan medoxomil and a CCB	Daiichi Sankyo Co., Ltd.	marketed	Angiotensin II receptor blocker / Calcium channel blocker combination	AT1 receptor; L-type voltage-gated calcium channel
valsartan/amlodpine	valsartan/amlodpine	University of Pavia	marketed	Angiotensin II receptor blocker / Calcium channel blocker combination	AT1 receptor / L-type calcium channel
olmesartan medoxomil / amlodipine or azelnidipine	olmesartan medoxomil / amlodipine or azelnidipine	COLM Study Research Organization	marketed	Angiotensin II receptor blocker / Calcium channel blocker combination	Angiotensin II type 1 receptor (AT1R); L-type voltage-gated calcium channels
valsartan/amlodipine	valsartan/amlodipine	Novartis	marketed	Angiotensin II receptor blocker / Calcium channel blocker combination	AT1 receptor / L-type calcium channel
Candemore Plus Tab	Candemore Plus Tab	Chong Kun Dang Pharmaceutical	marketed	Angiotensin II receptor blocker / Calcium channel blocker combination	AT1 receptor; L-type calcium channel
Candesartan cilexetil/Amlodipine besylate	Candesartan cilexetil/Amlodipine besylate	HK inno.N Corporation	marketed	Angiotensin II receptor blocker / Calcium channel blocker combination	AT1 receptor (angiotensin II type 1 receptor) / L-type voltage-gated calcium channel
Olmesartan/amlodipine	Olmesartan/amlodipine	Institut für Pharmakologie und Präventive Medizin	marketed	Angiotensin II receptor blocker / Calcium channel blocker combination	AT1 receptor (angiotensin II type 1 receptor) / L-type calcium channel

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor blocker / Calcium channel blocker combination class)

Handok Inc. · 3 drugs in this class
Institut für Pharmakologie und Präventive Medizin · 2 drugs in this class
Chong Kun Dang Pharmaceutical · 1 drug in this class
Daiichi Sankyo Co., Ltd. · 1 drug in this class
HK inno.N Corporation · 1 drug in this class
Novartis · 1 drug in this class
Boryung Pharmaceutical Co., Ltd · 1 drug in this class
University of Pavia · 1 drug in this class
COLM Study Research Organization · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). olmesartan medoxomil and a CCB — Competitive Intelligence Brief. https://druglandscape.com/ci/olmesartan-medoxomil-and-a-ccb. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab